利塞膦酸钠在防治绝经后骨质疏松症中的作用  

Risedronate sodium in prevention and treatment for postmenopausal osteoporosis

作　　者：姚斌[1] 许雯[1] 李建娟[1] 胡国亮[1] 翁建平[1] 梁奕铨[1] 胡少眉[1] 

机构地区：[1]中山大学附属第一医院内分泌科,广州510080

出　　处：《中华全科医师杂志》2004年第4期241-244,共4页Chinese Journal of General Practitioners

摘　　要：目的　观察利塞膦酸钠防治绝经后骨质疏松症的疗效。方法　绝经后骨质疏松症共4 8例 ,随机分为 2组 ,对照组 2 4例 ,服安慰剂 ;试验组 2 4例 ,服利塞膦酸钠 5mg/d。另外 ,两组患者每日均服钙维生素D3 合剂 (凯思立 ) 1片 ,两组共服药 12个月 ,试验后 0、1、3、6、9、12个月进行随访。结果　利塞膦酸钠组腰椎、股骨颈及大粗隆的骨密度均明显升高 (P <0 0 5 ) ,其中腰椎骨密度治疗前为 0 80± 0 0 9,治疗后 6个月及 12个月均达到 0 82± 0 0 9,增加率为 2 93%及 2 85 % ,均明显高于对照组 (P <0 0 5 )。 6个月及 12个月治疗总有效率试验组为 80 95 %及 71 4 3% ,显著高于对照组的4 5 4 5 %及 31 82 % (P <0 0 5 )。两组患者均无严重副作用。结论　利塞膦酸钠能明显提高绝经后骨质疏松症患者的骨密度 ,副作用轻。Objective To study the efficacy of risedronate sodium in prevention and treatment for postmenopausal osteoporosis. Methods Forty-eight cases of postmenopausal osteoporosis were randomly divided into two groups,a trail group (24 cases) treated with risedronate sodium and control group (24 cases) treated with placebo for twelve months,and both groups were suplemented with calcium carbonate (0.5 g/d) and vitamine D 3 (200 iu /d).All patients were followed up at 0,1,3,4,9 and 12th months. Results Bone mineral density (BMD) of lumbar vertebra,femoral neck,and greater trochanter increased significantly in risedronate group than that in control group( P <0.05). BMD of lumbar vertebra was 0.80±0.09 before treatment and 0.82±0.09 months and 12 months after treatment,with an increased rate of 2.93% and 2.85%,respectively. Overall effective rate in risedronate group was 80.95% and 71.43% 6 months and 12 months after treatment,respectively,significantly higher than that in control group, with 45.45% and 31.82%,respectively( P <0.05). No severe side effect was observed in both groups. Conclusions Risedronate sodium was could increase BMD in women with postmenopausal osteoporosis without severe side effect.

关 键 词：利塞膦酸钠 绝经期 骨质疏松症 骨密度 二磷酸盐 钙维生素D3合剂 

分 类 号：R58[医药卫生—内分泌]